Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma

Tomi Jun, MD
Published: Wednesday, May 31, 2017



Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).

Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.

Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.
 


Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).

Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.

Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x